• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » TCT 2013: Higher pacemaker rate marks difference between Medtronic’s, Edwards Lifesciences’ TAVI devices

TCT 2013: Higher pacemaker rate marks difference between Medtronic’s, Edwards Lifesciences’ TAVI devices

October 28, 2013 By Arezu Sarvestani

TCT 2013: Researchers find few differences between CoreValve and Sapien outcomes

Results from the PRAGMATIC Plus analysis of Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation system and Medtronic’s (NYSE:MDT) rivaling CoreValve device found few differences between the devices, with the exception of lower rates of permanent pacemaker implantation in patients who received Edwards’ Sapien device.

The so-called "pacemaker issue" has been a recurring topic at healthcare conferences since 1st publication earlier this year in the Journal of the American College of Cardiology, although the problem isn’t considered a safety risk.

"Importantly, there is no association between pacemaker implants and increased mortality, while other complications – such as stroke, PVL, rupture, and vascular complications – are much more worrisome because they can be dangerous and even life-threatening for patients," Medtronic told MassDevice.com today.

Medtronic further noted that findings from the PRAGMATIC Plus study are less significant, given that the study is a non-randomized, retrospective analysis, unlike the more robust clinical studies released by Medtronic. The Minnesota medical device giant plans this week to release a highly anticipated 1st look at data from its U.S. CoreValve pivotal trial.

The pacemaker issue came up several times during TAVI presentations at today’s Transcatheter Cardiovascular Therapeutics symposium in San Francisco. The difference may be a meaningful one for physicians deciding which device to implant, given that the PRAGAMATIC Plus analysis found no other differences reported in 30-day or 1-year mortality or combined safety endpoints between CoreValve and Sapien, according to a morning presentation at TCT.

Findings from the PRAGMATIC Plus study, presented by the San Raffaele Scientific Institute’s Dr. Alaide Chieffo, included pooled clinical and procedural characteristics and outcome data for nearly 800 patients who received TAVI treatment prior to July 2011. Results showed no significant differences at 30 days in all-cause mortality, cardiac mortality, heart attack, stroke, life-threatening bleeding or other safety outcomes.

Researchers did, however, find a statistically significant difference in patients requiring permanent pacemaker implants, with 22.5% of CoreValve patients requiring pacemakers compared with only 5.9% of Sapien patients, an outcome that Dr. Chieffo said was unsurprising.

Luckily the pacemaker issue may be on the decline. Researchers last year released study results finding that post-TAVI pacemaker use, once reported in 1 out of every 3 CoreValve procedures, had dropped as physicians developed strategies to avoid problems during TAVI implantation.

Researchers gathered at last year’s PCR London Valves 2012 meeting reported several methods for combating the need for pacemaker implantation following a CoreValve procedure, including avoiding pre-dilation, positioning the valve slightly higher in the heart and waiting for 10 days following the procedure before determining whether a pacemaker is needed.

A Swedish TAVI study showed that post-procedure pacemaker use was down to 11%, with data coming from a registry that included both CoreValve and Sapien.

Filed Under: News Well, Replacement Heart Valves Tagged With: Cardiac Rhythm Management, Clinical Trials, Conference coverage, Edwards Lifesciences, Minnesota, Transcatheter Cardiovascular Therapeutics symposium (TCT)

In case you missed it

  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
  • Teleflex wins Health Canada nod for Manta vascular closure device
  • Study shows strong performance, improved outcomes with Medtronic Evolut TAVR
  • New FDA clearance expands indications for Xact Robotics’ ablation system
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Avanos Medical recall of Cortrak 2 enteral access system is Class I
  • Jabil launches Qfinity reusable auto-injector
  • Launching your med device: A strategy & execution cross-functional guide
  • FDA allows booster dose Pfizer-BioNTech COVID-19 vaccine in children 5 to 11
  • FDA clears DePuy Synthes’ Inhance for total shoulder arthroplasty
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push

RSS From Medical Design & Outsourcing

  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]
  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no indication… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS